{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:25:34Z","timestamp":1707524734044},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,14]]},"DOI":"10.7759\/cureus.31468","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T09:02:24Z","timestamp":1668416544000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Clinical Experience of Rosuvastatin as a Lipid-Lowering Therapy for Primary and Secondary Prevention of Cardiovascular Events (REAL ROSE)"],"prefix":"10.7759","author":[{"given":"Ashwani","family":"Mehta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravikant","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Sashi Kant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjiv A","family":"Indurkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil Kumar","family":"Kota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santosh","family":"Revankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30407-8","article-title":"The changing patterns of cardiovascular diseases and their risk factors in the states of India: the Global Burden of Disease Study 1990-2016","volume":"6","author":"India State-Level Disease Burden Initiative CVD Collaborators","year":"2018","unstructured":"India State-Level Disease Burden Initiative CVD Collaborators. The changing patterns of cardiovascular diseases and their risk factors in the states of India: the Global Burden of Disease Study 1990-2016. Lancet Glob Health. 2018, 6:e1339-51. 10.1016\/S2214-109X(18)30407-8","journal-title":"Lancet Glob Health"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.118.005195","article-title":"Tackling the burden of cardiovascular diseases in India","volume":"12","author":"Abdul-Aziz AA","year":"2019","unstructured":"Abdul-Aziz AA, Desikan P, Prabhakaran D, Schroeder LF. Tackling the burden of cardiovascular diseases in India. Circ Cardiovasc Qual Outcomes. 2019, 12:e005195. 10.1161\/CIRCOUTCOMES.118.005195","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096808","article-title":"Prevalence of dyslipidemia in urban and rural India: the ICMR-INDIAB study","volume":"9","author":"Joshi SR","year":"2014","unstructured":"Joshi SR, Anjana RM, Deepa M, et al.. Prevalence of dyslipidemia in urban and rural India: the ICMR-INDIAB study. PLoS One. 2014, 9:e96808. 10.1371\/journal.pone.0096808","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2017.02.020","article-title":"Recent trends in epidemiology of dyslipidemias in India","volume":"69","author":"Gupta R","year":"2017","unstructured":"Gupta R, Rao RS, Misra A, Sharma SK. Recent trends in epidemiology of dyslipidemias in India. Indian Heart J. 2017, 69:382-92. 10.1016\/j.ihj.2017.02.020","journal-title":"Indian Heart J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.15836\/ccar2017.396","article-title":"The role of rosuvastatin in primary and secondary prevention of cardiovascular events and influence on patient compliance","volume":"12","author":"Rudan D","year":"2017","unstructured":"Rudan D. The role of rosuvastatin in primary and secondary prevention of cardiovascular events and influence on patient compliance. Cardiologia Croatica. 2017, 12:396-9. 10.15836\/ccar2017.396","journal-title":"Cardiologia Croatica"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4137\/CMC.S4324","article-title":"Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease","volume":"6","author":"Luvai A","year":"2012","unstructured":"Luvai A, Mbagaya W, Hall AS, Barth JH. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol. 2012, 6:17-33. 10.4137\/CMC.S4324","journal-title":"Clin Med Insights Cardiol"},{"key":"ref7","article-title":"Rosuvastatin: Role in secondary prevention of cardiovascular disease","volume":"66","author":"Wander GS","year":"2018","unstructured":"Wander GS, Hukkeri MYK, Yalagudri S, Mahajan B, Panda AT. Rosuvastatin: Role in secondary prevention of cardiovascular disease. J Assoc Physicians India. 2018, 66:70-4.","journal-title":"J Assoc Physicians India"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/2250-3528.186492","article-title":"Lipid association of India expert consensus statement on management of dyslipidemia in Indians 2016: part 1 - executive summary","volume":"5","author":"Iyengar SS","year":"2016","unstructured":"Iyengar SS, Puri R, Narasingan SN. Lipid association of India expert consensus statement on management of dyslipidemia in Indians 2016: part 1 - executive summary. J Clin Prev Cardiol. 2016, 5:51-61. 10.4103\/2250-3528.186492","journal-title":"J Clin Prev Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach F","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al.. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020, 41:111-88. 10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-ad08","article-title":"Addendum. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020;43(Suppl. 1):S111-S134","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. Addendum. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020;43(Suppl. 1):S111-S134. Diabetes Care. 2020, 43:1977-8. 10.2337\/dc20-ad08","journal-title":"Diabetes Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/2047487317708677","article-title":"Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome","volume":"24","author":"Schwartz GG","year":"2017","unstructured":"Schwartz GG, Fayyad R, Szarek M, DeMicco D, Olsson AG. Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome. Eur J Prev Cardiol. 2017, 24:1294-6. 10.1177\/2047487317708677","journal-title":"Eur J Prev Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.02.034","article-title":"Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"113","author":"Navarese EP","year":"2014","unstructured":"Navarese EP, Kowalewski M, Andreotti F, et al.. Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2014, 113:1753-64. 10.1016\/j.amjcard.2014.02.034","journal-title":"Am J Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2018.08.024","article-title":"Changes in coronary plaque composition in patients with acute myocardial infarction treated with high-intensity statin therapy (IBIS-4): a serial optical coherence tomography study","volume":"12","author":"R\u00e4ber L","year":"2019","unstructured":"R\u00e4ber L, Koskinas KC, Yamaji K, et al.. Changes in coronary plaque composition in patients with acute myocardial infarction treated with high-intensity statin therapy (IBIS-4): a serial optical coherence tomography study. JACC Cardiovasc Imaging. 2019, 12:1518-28. 10.1016\/j.jcmg.2018.08.024","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-017-0519-1","article-title":"Lipid management in India: a nationwide, cross-sectional physician survey","volume":"16","author":"Wander GS","year":"2017","unstructured":"Wander GS, Jadhav UM, Chemburkar A, Lopez M, Gogtay J. Lipid management in India: a nationwide, cross-sectional physician survey. Lipids Health Dis. 2017, 16:130. 10.1186\/s12944-017-0519-1","journal-title":"Lipids Health Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco P","year":"2006","unstructured":"Amarenco P, Bogousslavsky J, Callahan A 3rd, et al.. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006, 355:549-59. 10.1056\/NEJMoa061894","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70058-4","article-title":"Lipid management in the prevention of stroke: Review and updated meta-analysis of statins for stroke prevention","volume":"8","author":"Amarenco P","year":"2009","unstructured":"Amarenco P, Labreuche J. Lipid management in the prevention of stroke: Review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009, 8:453-63. 10.1016\/S1474-4422(09)70058-4","journal-title":"Lancet Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"50","author":"Powers WJ","year":"2019","unstructured":"Powers WJ, Rabinstein AA, Ackerson T, et al.. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2019, 50:e344-418. 10.1161\/STR.0000000000000211","journal-title":"Stroke"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/17584299.2017.1383700","article-title":"Lipid Association of India (LAI) expert consensus statement on management of dyslipidaemia in Indians 2017: part 2","volume":"12","author":"Iyengar SS","year":"2017","unstructured":"Iyengar SS, Puri R, Narasingan SN, et al.. Lipid Association of India (LAI) expert consensus statement on management of dyslipidaemia in Indians 2017: part 2. Clin Lipidology. 2017, 12:56-109. 10.1080\/17584299.2017.1383700","journal-title":"Clin Lipidology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_546_20","article-title":"Risk factors, comorbiditiEs and Atherogenic dysLipidaemia in Indian YOUNG patients with dyslipidaemia attending hospital\/clinic: REAL YOUNG (dyslipidaemia) study","volume":"9","author":"Iyengar SS","year":"2020","unstructured":"Iyengar SS, Narasingan SN, Gandhi P, et al.. Risk factors, comorbiditiEs and Atherogenic dysLipidaemia in Indian YOUNG patients with dyslipidaemia attending hospital\/clinic: REAL YOUNG (dyslipidaemia) study. J Family Med Prim Care. 2020, 9:4156-64. 10.4103\/jfmpc.jfmpc_546_20","journal-title":"J Family Med Prim Care"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2016\/18683.8191","article-title":"Vascular disease in young Indians (20-40 years): role of dyslipidemia","volume":"10","author":"Dalal J","year":"2016","unstructured":"Dalal J, Deb PK, Shrivastava S, Rao MS, Mohan JC, Kumar AS. Vascular disease in young Indians (20-40 years): role of dyslipidemia. J Clin Diagn Res. 2016, 10:OE01-5. 10.7860\/JCDR\/2016\/18683.8191","journal-title":"J Clin Diagn Res"},{"key":"ref21","article-title":"Clinical utilization pattern of multiple strengths of glimepiride and metformin fixed dose combinations in Indian type 2 diabetes patients","volume":"68","author":"Unnikrishnan AG","year":"2020","unstructured":"Unnikrishnan AG, Pandit K, George J, Venkataraman S, Abhyankar MV. Clinical utilization pattern of multiple strengths of glimepiride and metformin fixed dose combinations in Indian type 2 diabetes patients. J Assoc Physicians India. 2020, 68:57-61.","journal-title":"J Assoc Physicians India"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone NJ","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al.. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014, 129:S1-45. 10.1161\/01.cir.0000437738.63853.7a","journal-title":"Circulation"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000624","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy SM","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al.. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019, 139:e1046-81. 10.1161\/CIR.0000000000000624","journal-title":"Circulation"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan WN","year":"2014","unstructured":"Kernan WN, Ovbiagele B, Black HR, et al.. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2014, 45:2160-236. 10.1161\/STR.0000000000000024","journal-title":"Stroke"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent C","year":"2009","unstructured":"Baigent C, Blackwell L, Collins R, et al.. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009, 373:1849-60. 10.1016\/S0140-6736(09)60503-1","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli MF","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, et al.. 2016 European guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016, 37:2315-81. 10.1093\/eurheartj\/ehw106","journal-title":"Eur Heart J"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman L","year":"2018","unstructured":"Bowman L, Mafham M, Wallendszus K, et al.. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018, 379:1529-39. 10.1056\/NEJMoa1804988","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil JJ","year":"2018","unstructured":"McNeil JJ, Wolfe R, Woods RL, et al.. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018, 379:1509-18. 10.1056\/NEJMoa1805819","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000678","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett DK","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al.. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019, 140:e596-646. 10.1161\/CIR.0000000000000678","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/95207-real-world-clinical-experience-of-rosuvastatin-as-a-lipid-lowering-therapy-for-primary-and-secondary-prevention-of-cardiovascular-events-real-rose","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:41:16Z","timestamp":1707507676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/95207-real-world-clinical-experience-of-rosuvastatin-as-a-lipid-lowering-therapy-for-primary-and-secondary-prevention-of-cardiovascular-events-real-rose"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.31468","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,14]]}}}